An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

Not Applicable

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Allopurinal

• Registration Number: NCT00823199
• Lead Sponsor: Bronx Psychiatric Center

Brief Summary

This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11
• Primary Completion: 2008-08
• Study Completion: 2008-08
• Study First Submitted: 2009-01-14
• Study First Submitted QC: 2009-01-14
• Study First Posted: 2009-01-15
• Results First Submitted: 2012-04-25
• Results First Submitted QC: 2013-03-21
• Results First Posted: 2013-05-03
• Status Verified: 2018-07
• Last Update Submitted: 2018-07-23
• Last Update Posted: 2018-08-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms)

Exclusion Criteria

• Over 65
• Renal or liver disease
• Diabetes
• Hypertension
• Taking thiazides or ACE inhibitors

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Allopurinal treatment	Allopurinal	Allopurinal 300mg once daily by mouth for four weeks

Primary Outcome Measures

Name	Time	Method
Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia	baseline and 4 weeks	Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)

Secondary Outcome Measures

Name	Time	Method
Simpson Angus Scale for Parkinsonism	baseline and 4 weeks	Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)